Filter posts

Small Companies, Big Returns

The broader biotech indices are up more than 30 percent this year and have reached …

Big Ventures

It is rare to see triple digit millions in private financing rounds, but it does …

The Good, the Bad, and the Ugly for Biotech IPOs

The troubles in the biotech IPO market are complicated to explain to industry outsiders. They …

BIO Investor Forum: The New Kids on the Biotech Block

Where should biotech start-ups look for funding in the venture capital desert that is becoming …

How does the NBI perform in the last quarter of the year?

Does the NASDAQ Biotech Index (NBI) outperform the broader market in the last three months …

Recommended Reading from BIOtechNOW

We hope the dust has settled from Boston’s International Convention, and you’re ready for a …

Indices, IPOs, and New Drug Approvals – Update July 6th 2012

1. Stock Performance. The Nasdaq Biotech Index (NBI) continued on its path of outperforming the …

Business Confidence with the RFS Under Attack

This week, Biofuels Digest and BIO launched the quarterly Bioenergy Business Outlook Survey. Results from …

Only a Few Public Biotechs are Profitable, but There are More of Them Today

Of the 294 biotechs trading on public exchanges today, 248 (84%) focus on drug development. …

Indices, IPOs, and New Drug Approvals - Update April 3rd 2012

1. Stock Performance. The Nasdaq Biotech Index (NBI) continued to outperform in March, maintaining its …